Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
…
continue reading
The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
34:45
34:45
Play later
Play later
Lists
Like
Liked
34:45
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Current Clinical Practice and NCCN Guidelines for CLL/SLL
31:33
31:33
Play later
Play later
Lists
Like
Liked
31:33
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Blood Global Hematology Editor-in-Chief Shares Vision
16:40
16:40
Play later
Play later
Lists
Like
Liked
16:40
In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Jorge Cortes, MD, the inaugural editor-in-chief of Blood Global Hematology, one of the latest additions to the growing Blood journals portfolio. Dr. Cortes, director of the Georgia Cancer Center at Augusta University, shares …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma
1:00:49
1:00:49
Play later
Play later
Lists
Like
Liked
1:00:49
Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
28:35
28:35
Play later
Play later
Lists
Like
Liked
28:35
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
24:23
24:23
Play later
Play later
Lists
Like
Liked
24:23
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
24:30
24:30
Play later
Play later
Lists
Like
Liked
24:30
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for AML
25:21
25:21
Play later
Play later
Lists
Like
Liked
25:21
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
19:19
19:19
Play later
Play later
Lists
Like
Liked
19:19
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis
1:00:06
1:00:06
Play later
Play later
Lists
Like
Liked
1:00:06
Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD
…
continue reading
In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapy at Stanford University in California, talks with Fred Appelbaum, MD, executive vice president and deputy director at the Fred Hutchinson Cancer Center in Seattle, and a professor of medic…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms
23:49
23:49
Play later
Play later
Lists
Like
Liked
23:49
In this episode, Contributing Editor Bethan Psaila, MD, PhD, an associate professor of hematology at the University of Oxford’s MRC Weatherall Institute of Molecular Medicine, talks with Andrew Dunbar, MD, an assistant professor and independent lab investigator at MD Anderson Cancer Center in Houston, Texas. They discuss Dr. Dunbar’s paper recently…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences
1:16:45
1:16:45
Play later
Play later
Lists
Like
Liked
1:16:45
Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
33:54
33:54
Play later
Play later
Lists
Like
Liked
33:54
Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma
42:08
42:08
Play later
Play later
Lists
Like
Liked
42:08
Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia
1:02:06
1:02:06
Play later
Play later
Lists
Like
Liked
1:02:06
Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
25:55
25:55
Play later
Play later
Lists
Like
Liked
25:55
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47:23
47:23
Play later
Play later
Lists
Like
Liked
47:23
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives
25:41
25:41
Play later
Play later
Lists
Like
Liked
25:41
In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon, MD, an attending physician in the division of angiology and hemostasis with the University Hospitals of Geneva (Switzerland). They talk about a paper co-authored by Dr. Blondon title…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series
1:01:09
1:01:09
Play later
Play later
Lists
Like
Liked
1:01:09
Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria
1:37:16
1:37:16
Play later
Play later
Lists
Like
Liked
1:37:16
Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences
1:04:36
1:04:36
Play later
Play later
Lists
Like
Liked
1:04:36
Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Growing the Next Generation of Hematologists
20:14
20:14
Play later
Play later
Lists
Like
Liked
20:14
In this episode, Editor-in-Chief Shaji Kumar, MD, a professor of medicine at Mayo Clinic in Rochester, Minnesota, talks with Leslie Ellis, MD, a professor of internal medicine at Atrium Health Wake Forest Baptist in Winston Salem, North Carolina. They discuss the ASH Ambassador Program, which is designed to support the recruitment and retention of …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences
1:35:11
1:35:11
Play later
Play later
Lists
Like
Liked
1:35:11
Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
48:15
48:15
Play later
Play later
Lists
Like
Liked
48:15
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma
1:00:13
1:00:13
Play later
Play later
Lists
Like
Liked
1:00:13
Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.By Neil Love, MD
…
continue reading
In this episode, Tamara Dunn, MD, a clinical associate professor of medicine in the division of hematology at Stanford University in Stanford, California, and co-chair of ASH’s Women in Hematology Working Group, hosts a conversation with Toyosi Onwuemene, MD, an associate professor of medicine, specializing in hemostasis/thrombosis, at Duke Univers…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
36:29
36:29
Play later
Play later
Lists
Like
Liked
36:29
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatmen…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Four Is Better Than Three: Will We Finally Agree?
23:18
23:18
Play later
Play later
Lists
Like
Liked
23:18
In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, B…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series
1:00:12
1:00:12
Play later
Play later
Lists
Like
Liked
1:00:12
Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.By Research To Practice
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia
58:01
58:01
Play later
Play later
Lists
Like
Liked
58:01
Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.By Neil Love, MD
…
continue reading
In this episode, Contributing Editor Lori Muffly, MD, an associate professor of medicine specializing in blood and marrow transplantation and cellular therapies at Stanford University in California, talks with Roberta Demichelis, MD, an assistant professor in the department of hematology and oncology at the Salvador Zubirán National Institute of He…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series
1:00:25
1:00:25
Play later
Play later
Lists
Like
Liked
1:00:25
Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Current Considerations for Adverse Event Management With HER3-Directed Agents
12:33
12:33
Play later
Play later
Lists
Like
Liked
12:33
The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
15:24
15:24
Play later
Play later
Lists
Like
Liked
15:24
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab The HER2xHER3 bispecific antibody zenocutuzumab The HER3-targeted anti…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
8:54
8:54
Play later
Play later
Lists
Like
Liked
8:54
This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD A…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
30:29
30:29
Play later
Play later
Lists
Like
Liked
30:29
In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including: Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or plac…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis
19:33
19:33
Play later
Play later
Lists
Like
Liked
19:33
In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including: Navitoclax (BCL-XL/BCL-2 inhibitor) Pelabresib (BET inhibitor) Imetelstat (telomerase inhibitor) Luspatercept (erythroid maturation agent) Additional strategies Presenter: Jacqueline S. …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia
16:13
16:13
Play later
Play later
Lists
Like
Liked
16:13
In this episode, Contributing Editor Sarah Tasian, MD, associate professor at the University of Pennsylvania School of Medicine and chief of the hematologic malignancies program at the Children’s Hospital of Philadelphia, talks with Rob Pieters, MD, the chief medical officer at the Princess Maxima Center for Pediatric Oncology and professor of pedi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A Year in Review and a Look to the Future: BTKi in CLL and MCL
27:33
27:33
Play later
Play later
Lists
Like
Liked
27:33
In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: SHINE: First-Line Ibrutinib + Bendam…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
33:18
33:18
Play later
Play later
Lists
Like
Liked
33:18
In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including: Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclit…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series
1:01:30
1:01:30
Play later
Play later
Lists
Like
Liked
1:01:30
Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insights and Considerations for Precision Care With HER3-Targeted Agents in NSCLC and Breast Cancer
38:51
38:51
Play later
Play later
Lists
Like
Liked
38:51
In this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Improving Care for Black Patients With Endometrial Cancer
26:58
26:58
Play later
Play later
Lists
Like
Liked
26:58
In this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include: Data on racial disparities in EC survival Importance of listening to Black patients to better…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series
1:01:44
1:01:44
Play later
Play later
Lists
Like
Liked
1:01:44
Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Editors-in-Chief of Two New ASH Journals Share Their Visions
25:16
25:16
Play later
Play later
Lists
Like
Liked
25:16
In this episode, Dr. Shaji Kumar, editor-in-chief of The Hematologist, has a conversation with Drs. Jonathan Licht and Keith McCrae, the editors-in-chief, respectively, of ASH's two new journals Blood Neoplasia and Blood Vessels, Thrombosis & Hemostasis. Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: B…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma
1:01:33
1:01:33
Play later
Play later
Lists
Like
Liked
1:01:33
Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences
1:19:48
1:19:48
Play later
Play later
Lists
Like
Liked
1:19:48
Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
24:54
24:54
Play later
Play later
Lists
Like
Liked
24:54
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including: Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/R…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar
46:27
46:27
Play later
Play later
Lists
Like
Liked
46:27
Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.By Neil Love, MD
…
continue reading